Baxter International Inc. (NYSE: BAX) Stock Competitors & Peer Comparison
See BAX's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BAX and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BAX | $26.73 | -1.18% | 13.8B | 12.85 | $2.08 | +0.75% |
| ISRG | $394.51 | -1.68% | 139.4B | 41.01 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.04% |
| BDX | $183.40 | +0.79% | 50.5B | 14.11 | $13.00 | +2.04% |
| MDLN | $35.74 | +0.45% | 30.2B | 26.19 | $1.36 | N/A |
| WST | $349.42 | +0.94% | 24.6B | 43.83 | $7.97 | +0.25% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $88.59 | +2.46% | 15.3B | 12.48 | $7.10 | N/A |
| COO | $76.17 | -0.56% | 14.9B | 16.70 | $4.56 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.04% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
BAX vs ISRG Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, ISRG has a market cap of 139.4B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while ISRG trades at $394.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas ISRG's P/E ratio is 41.01. In terms of profitability, BAX's ROE is -0.17%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, BAX is less volatile compared to ISRG. This indicates lower risk in terms of short-term price fluctuations for BAX.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
BAX vs BDXA Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas BDXA's P/E ratio is 45.70. In terms of profitability, BAX's ROE is -0.17%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, BAX is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for BAX.Check BDXA's competition here
Becton, Dickinson and Company (NYSE: BDX)
BAX vs BDX Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, BDX has a market cap of 50.5B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while BDX trades at $183.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas BDX's P/E ratio is 14.11. In terms of profitability, BAX's ROE is -0.17%, compared to BDX's ROE of +0.04%. Regarding short-term risk, BAX is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for BAX.Check BDX's competition here
Medline Inc. (NASDAQ: MDLN)
BAX vs MDLN Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, MDLN has a market cap of 30.2B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while MDLN trades at $35.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas MDLN's P/E ratio is 26.19. In terms of profitability, BAX's ROE is -0.17%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, BAX is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for BAX.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
BAX vs WST Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, WST has a market cap of 24.6B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while WST trades at $349.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas WST's P/E ratio is 43.83. In terms of profitability, BAX's ROE is -0.17%, compared to WST's ROE of +0.19%. Regarding short-term risk, BAX is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for BAX.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
BAX vs HOLX Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas HOLX's P/E ratio is 31.54. In terms of profitability, BAX's ROE is -0.17%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, BAX is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for BAX.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
BAX vs SOLV Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, SOLV has a market cap of 15.3B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while SOLV trades at $88.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas SOLV's P/E ratio is 12.48. In terms of profitability, BAX's ROE is -0.17%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, BAX is less volatile compared to SOLV. This indicates lower risk in terms of short-term price fluctuations for BAX.Check SOLV's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
BAX vs COO Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, COO has a market cap of 14.9B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while COO trades at $76.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas COO's P/E ratio is 16.70. In terms of profitability, BAX's ROE is -0.17%, compared to COO's ROE of +0.03%. Regarding short-term risk, BAX is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for BAX.Check COO's competition here
Becton, Dickinson and Company (NYSE: BDXB)
BAX vs BDXB Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas BDXB's P/E ratio is 7.60. In terms of profitability, BAX's ROE is -0.17%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, BAX is less volatile compared to BDXB. This indicates lower risk in terms of short-term price fluctuations for BAX.Check BDXB's competition here
Repligen Corporation (NASDAQ: RGEN)
BAX vs RGEN Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, RGEN has a market cap of 9.4B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while RGEN trades at $166.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas RGEN's P/E ratio is 92.68. In terms of profitability, BAX's ROE is -0.17%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, BAX is more volatile compared to RGEN. This indicates higher risk in terms of short-term price fluctuations for BAX.Check RGEN's competition here
Avantor, Inc. (NYSE: AVTR)
BAX vs AVTR Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, AVTR has a market cap of 9.2B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while AVTR trades at $13.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas AVTR's P/E ratio is 16.07. In terms of profitability, BAX's ROE is -0.17%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, BAX is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for BAX.Check AVTR's competition here
AptarGroup, Inc. (NYSE: ATR)
BAX vs ATR Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while ATR trades at $132.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas ATR's P/E ratio is 23.09. In terms of profitability, BAX's ROE is -0.17%, compared to ATR's ROE of +0.14%. Regarding short-term risk, BAX is less volatile compared to ATR. This indicates lower risk in terms of short-term price fluctuations for BAX.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
BAX vs BLCO Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, BLCO has a market cap of 6.1B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while BLCO trades at $17.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas BLCO's P/E ratio is 26.20. In terms of profitability, BAX's ROE is -0.17%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, BAX is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for BAX.Check BLCO's competition here
Teleflex Incorporated (NYSE: TFX)
BAX vs TFX Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, TFX has a market cap of 6.1B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while TFX trades at $137.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas TFX's P/E ratio is 15.67. In terms of profitability, BAX's ROE is -0.17%, compared to TFX's ROE of -0.32%. Regarding short-term risk, BAX is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for BAX.Check TFX's competition here
Stevanato Group S.p.A. (NYSE: STVN)
BAX vs STVN Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, STVN has a market cap of 5.8B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while STVN trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas STVN's P/E ratio is 32.01. In terms of profitability, BAX's ROE is -0.17%, compared to STVN's ROE of +0.09%. Regarding short-term risk, BAX is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for BAX.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
BAX vs MMSI Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, MMSI has a market cap of 5.4B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while MMSI trades at $90.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas MMSI's P/E ratio is 23.21. In terms of profitability, BAX's ROE is -0.17%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, BAX is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for BAX.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
BAX vs ICUI Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, ICUI has a market cap of 4.6B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while ICUI trades at $182.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas ICUI's P/E ratio is 22.84. In terms of profitability, BAX's ROE is -0.17%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, BAX is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for BAX.Check ICUI's competition here
Envista Holdings Corp (NYSE: NVST)
BAX vs NVST Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, NVST has a market cap of 4.6B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while NVST trades at $28.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas NVST's P/E ratio is 19.10. In terms of profitability, BAX's ROE is -0.17%, compared to NVST's ROE of +0.04%. Regarding short-term risk, BAX is more volatile compared to NVST. This indicates higher risk in terms of short-term price fluctuations for BAX.Check NVST's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
BAX vs PLSE Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, PLSE has a market cap of 3.1B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while PLSE trades at $44.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas PLSE's P/E ratio is -37.75. In terms of profitability, BAX's ROE is -0.17%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, BAX is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for BAX.Check PLSE's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
BAX vs XRAY Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, XRAY has a market cap of 2.3B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while XRAY trades at $11.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas XRAY's P/E ratio is 8.10. In terms of profitability, BAX's ROE is -0.17%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, BAX is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for BAX.Check XRAY's competition here
AtriCure, Inc. (NASDAQ: ATRC)
BAX vs ATRC Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, ATRC has a market cap of 2.3B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while ATRC trades at $44.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas ATRC's P/E ratio is 1375.78. In terms of profitability, BAX's ROE is -0.17%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, BAX is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for BAX.Check ATRC's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
BAX vs LMAT Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, LMAT has a market cap of 1.9B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while LMAT trades at $82.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas LMAT's P/E ratio is 30.29. In terms of profitability, BAX's ROE is -0.17%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, BAX is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for BAX.Check LMAT's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
BAX vs BLFS Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, BLFS has a market cap of 1.7B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while BLFS trades at $35.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas BLFS's P/E ratio is -165.93. In terms of profitability, BAX's ROE is -0.17%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, BAX is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for BAX.Check BLFS's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
BAX vs KMTS Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, KMTS has a market cap of 1.6B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while KMTS trades at $28.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas KMTS's P/E ratio is -11.87. In terms of profitability, BAX's ROE is -0.17%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, BAX is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for BAX.Check KMTS's competition here
Azenta, Inc. (NASDAQ: AZTA)
BAX vs AZTA Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, AZTA has a market cap of 1.5B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while AZTA trades at $33.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas AZTA's P/E ratio is 79.48. In terms of profitability, BAX's ROE is -0.17%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, BAX is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for BAX.Check AZTA's competition here
STAAR Surgical Company (NASDAQ: STAA)
BAX vs STAA Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, STAA has a market cap of 1.3B. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while STAA trades at $26.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas STAA's P/E ratio is 45.93. In terms of profitability, BAX's ROE is -0.17%, compared to STAA's ROE of +0.01%. Regarding short-term risk, BAX is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for BAX.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
BAX vs QDEL Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, QDEL has a market cap of 975.1M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while QDEL trades at $14.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas QDEL's P/E ratio is 10.67. In terms of profitability, BAX's ROE is -0.17%, compared to QDEL's ROE of -0.55%. Regarding short-term risk, BAX is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for BAX.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
BAX vs ATRI Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas ATRI's P/E ratio is 64.50. In terms of profitability, BAX's ROE is -0.17%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, BAX is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for BAX.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
BAX vs ANGO Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, ANGO has a market cap of 655.1M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while ANGO trades at $15.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas ANGO's P/E ratio is -40.64. In terms of profitability, BAX's ROE is -0.17%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, BAX is less volatile compared to ANGO. This indicates lower risk in terms of short-term price fluctuations for BAX.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
BAX vs NNNN Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, NNNN has a market cap of 381.9M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while NNNN trades at $8.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas NNNN's P/E ratio is 125.72. In terms of profitability, BAX's ROE is -0.17%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, BAX is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for BAX.Check NNNN's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
BAX vs SMTI Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, SMTI has a market cap of 313.9M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while SMTI trades at $34.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas SMTI's P/E ratio is -569.17. In terms of profitability, BAX's ROE is -0.17%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, BAX is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for BAX.Check SMTI's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
BAX vs OSUR Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, OSUR has a market cap of 264.4M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while OSUR trades at $3.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas OSUR's P/E ratio is -6.98. In terms of profitability, BAX's ROE is -0.17%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, BAX is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for BAX.Check OSUR's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
BAX vs INFU Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, INFU has a market cap of 247M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while INFU trades at $12.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas INFU's P/E ratio is 29.85. In terms of profitability, BAX's ROE is -0.17%, compared to INFU's ROE of +0.15%. Regarding short-term risk, BAX is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for BAX.Check INFU's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
BAX vs UTMD Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, UTMD has a market cap of 226.1M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while UTMD trades at $71.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas UTMD's P/E ratio is 21.01. In terms of profitability, BAX's ROE is -0.17%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, BAX is less volatile compared to UTMD. This indicates lower risk in terms of short-term price fluctuations for BAX.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
BAX vs PDEX Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, PDEX has a market cap of 214M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while PDEX trades at $67.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas PDEX's P/E ratio is 23.60. In terms of profitability, BAX's ROE is -0.17%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, BAX is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for BAX.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
BAX vs KRMD Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, KRMD has a market cap of 156.2M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while KRMD trades at $3.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas KRMD's P/E ratio is -85.00. In terms of profitability, BAX's ROE is -0.17%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, BAX is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for BAX.Check KRMD's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
BAX vs MBOT Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, MBOT has a market cap of 70.6M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while MBOT trades at $1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas MBOT's P/E ratio is -5.96. In terms of profitability, BAX's ROE is -0.17%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, BAX is less volatile compared to MBOT. This indicates lower risk in terms of short-term price fluctuations for BAX.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
BAX vs AKYA Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas AKYA's P/E ratio is -1.34. In terms of profitability, BAX's ROE is -0.17%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, BAX is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for BAX.Check AKYA's competition here
Daxor Corporation (NASDAQ: DXR)
BAX vs DXR Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, DXR has a market cap of 60.7M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while DXR trades at $10.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas DXR's P/E ratio is 27.20. In terms of profitability, BAX's ROE is -0.17%, compared to DXR's ROE of +0.22%. Regarding short-term risk, BAX is less volatile compared to DXR. This indicates lower risk in terms of short-term price fluctuations for BAX.Check DXR's competition here
SkyAI, Inc. (NASDAQ: STSS)
BAX vs STSS Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas STSS's P/E ratio is -0.02. In terms of profitability, BAX's ROE is -0.17%, compared to STSS's ROE of -1.54%. Regarding short-term risk, BAX is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for BAX.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
BAX vs OMIC Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas OMIC's P/E ratio is -0.58. In terms of profitability, BAX's ROE is -0.17%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, BAX is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for BAX.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
BAX vs IGAP Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas IGAP's P/E ratio is -10.52. In terms of profitability, BAX's ROE is -0.17%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, BAX is less volatile compared to IGAP. This indicates lower risk in terms of short-term price fluctuations for BAX.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
BAX vs NEPH Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, NEPH has a market cap of 50.2M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while NEPH trades at $4.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas NEPH's P/E ratio is 77.08. In terms of profitability, BAX's ROE is -0.17%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, BAX is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for BAX.Check NEPH's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
BAX vs POCI Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, POCI has a market cap of 48M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while POCI trades at $4.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas POCI's P/E ratio is -6.09. In terms of profitability, BAX's ROE is -0.17%, compared to POCI's ROE of -0.37%. Regarding short-term risk, BAX is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for BAX.Check POCI's competition here
Milestone Scientific Inc. (AMEX: MLSS)
BAX vs MLSS Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, MLSS has a market cap of 43.8M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while MLSS trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas MLSS's P/E ratio is -8.25. In terms of profitability, BAX's ROE is -0.17%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, BAX is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for BAX.Check MLSS's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
BAX vs HBIO Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, HBIO has a market cap of 30M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while HBIO trades at $6.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas HBIO's P/E ratio is -18.49. In terms of profitability, BAX's ROE is -0.17%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, BAX is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for BAX.Check HBIO's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
BAX vs SDC Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas SDC's P/E ratio is -0.03. In terms of profitability, BAX's ROE is -0.17%, compared to SDC's ROE of -1.96%. Regarding short-term risk, BAX is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for BAX.Check SDC's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
BAX vs ZJYL Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, ZJYL has a market cap of 26.5M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while ZJYL trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas ZJYL's P/E ratio is 21.13. In terms of profitability, BAX's ROE is -0.17%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, BAX is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for BAX.Check ZJYL's competition here
Invacare Corporation (NYSE: IVC)
BAX vs IVC Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas IVC's P/E ratio is -0.79. In terms of profitability, BAX's ROE is -0.17%, compared to IVC's ROE of -0.46%. Regarding short-term risk, BAX is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for BAX.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
BAX vs RVP Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, RVP has a market cap of 20.7M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while RVP trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas RVP's P/E ratio is -2.10. In terms of profitability, BAX's ROE is -0.17%, compared to RVP's ROE of -0.08%. Regarding short-term risk, BAX is less volatile compared to RVP. This indicates lower risk in terms of short-term price fluctuations for BAX.Check RVP's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
BAX vs RGNT Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, RGNT has a market cap of 13.8M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while RGNT trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas RGNT's P/E ratio is -0.08. In terms of profitability, BAX's ROE is -0.17%, compared to RGNT's ROE of N/A. Regarding short-term risk, BAX is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for BAX.Check RGNT's competition here
Femasys Inc. (NASDAQ: FEMY)
BAX vs FEMY Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, FEMY has a market cap of 6.9M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while FEMY trades at $2.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas FEMY's P/E ratio is -6.33. In terms of profitability, BAX's ROE is -0.17%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, BAX is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for BAX.Check FEMY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
BAX vs NSTG Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas NSTG's P/E ratio is -0.03. In terms of profitability, BAX's ROE is -0.17%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, BAX is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for BAX.Check NSTG's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
BAX vs NXGL Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, NXGL has a market cap of 4.8M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while NXGL trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas NXGL's P/E ratio is -1.45. In terms of profitability, BAX's ROE is -0.17%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, BAX is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for BAX.Check NXGL's competition here
Lucyd, Inc (NASDAQ: LUCY)
BAX vs LUCY Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, LUCY has a market cap of 4.6M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while LUCY trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas LUCY's P/E ratio is -0.43. In terms of profitability, BAX's ROE is -0.17%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, BAX is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for BAX.Check LUCY's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
BAX vs POAI Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas POAI's P/E ratio is -0.03. In terms of profitability, BAX's ROE is -0.17%, compared to POAI's ROE of -107.05%. Regarding short-term risk, BAX is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for BAX.Check POAI's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
BAX vs GCTK Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, GCTK has a market cap of 2.8M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while GCTK trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas GCTK's P/E ratio is -0.02. In terms of profitability, BAX's ROE is -0.17%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, BAX is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for BAX.Check GCTK's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
BAX vs MHUA Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas MHUA's P/E ratio is 0.25. In terms of profitability, BAX's ROE is -0.17%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, BAX is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for BAX.Check MHUA's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
BAX vs GMVD Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas GMVD's P/E ratio is -0.01. In terms of profitability, BAX's ROE is -0.17%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, BAX is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for BAX.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
BAX vs GMVDW Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas GMVDW's P/E ratio is N/A. In terms of profitability, BAX's ROE is -0.17%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, BAX is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for BAX.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
BAX vs AVGR Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas AVGR's P/E ratio is -0.05. In terms of profitability, BAX's ROE is -0.17%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, BAX is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for BAX.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
BAX vs NXGLW Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, NXGLW has a market cap of 1.2M. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas NXGLW's P/E ratio is -0.04. In terms of profitability, BAX's ROE is -0.17%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, BAX is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for BAX.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
BAX vs LUCYW Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas LUCYW's P/E ratio is N/A. In terms of profitability, BAX's ROE is -0.17%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, BAX is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for BAX.Check LUCYW's competition here
Invuity, Inc. (NASDAQ: IVTY)
BAX vs IVTY Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas IVTY's P/E ratio is -3.80. In terms of profitability, BAX's ROE is -0.17%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, BAX is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for BAX.Check IVTY's competition here
Analogic Corporation (NASDAQ: ALOG)
BAX vs ALOG Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas ALOG's P/E ratio is 40.93. In terms of profitability, BAX's ROE is -0.17%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, BAX is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for BAX.Check ALOG's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
BAX vs HRC Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, HRC has a market cap of 0. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas HRC's P/E ratio is 41.92. In terms of profitability, BAX's ROE is -0.17%, compared to HRC's ROE of +0.14%. Regarding short-term risk, BAX is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for BAX.Check HRC's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
BAX vs ATRS Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas ATRS's P/E ratio is 14.95. In terms of profitability, BAX's ROE is -0.17%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, BAX is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for BAX.Check ATRS's competition here
Apria, Inc. (NASDAQ: APR)
BAX vs APR Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, APR has a market cap of 0. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas APR's P/E ratio is 22.59. In terms of profitability, BAX's ROE is -0.17%, compared to APR's ROE of +9.81%. Regarding short-term risk, BAX is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for BAX.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
BAX vs IIN Comparison August 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 13.8B. In comparison, IIN has a market cap of 0. Regarding current trading prices, BAX is priced at $26.73 on the NYSE, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 12.85, whereas IIN's P/E ratio is 226.45. In terms of profitability, BAX's ROE is -0.17%, compared to IIN's ROE of -0.00%. Regarding short-term risk, BAX is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for BAX.Check IIN's competition here